Abstract Details

Title Perampanel Discontinuation Is Not Associated With Self-Reported Withdrawal Symptoms in Patients Completing Phase III Clinical Studies

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) (-)

Poster/Presentation
Number 232

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Michael A. Rogawski, MD, PhD (University of California - Davis) PRESENTER	Dr. Rogawski has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Xenon Pharmaceuticals.
Peter A. LeWitt, MD (Henry Ford Hospital - Franklin Pointe)	Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ONO Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. LeWitt has received research support from Michael J Fox Foundation.
Haichen Yang, MD (Amicus Therapeutics)	No disclosure on file
	No disclosure on file
Betsy N. Williams, PhD	Dr. Williams has received personal compensation for serving as an employee of IQVIA.
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��